Beijing Remate Medical Technology Co., Ltd. 2025 Annual Report of Independent Director
To the Shareholders and Shareholder Representatives:
I, (Sun Peirui), as an independent director of Beijing Remate Medical Technology Co., Ltd. (hereinafter referred to as the "Company"), have strictly followed the requirements of the "Company Law," "Securities Law," "Administrative Measures for Independent Directors of Listed Companies," and the "Articles of Association of Beijing Remate Medical Technology Co., Ltd." (hereinafter referred to as the "Articles of Association") in 2025. I have honestly, diligently, and independently performed my duties, actively attended relevant meetings, conscientiously reviewed all proposals submitted to the Board of Directors, provided independent opinions on major company matters, and effectively protected the interests of the Company and shareholders, thereby playing a good role in exercising the independence and professionalism of an independent director. The following is a report on my performance of independent director duties in 2025:
I. Basic Information
I, Sun Peirui, male, born in 1983, am a Chinese national with no overseas residency. I hold a Bachelor of Laws degree from Hebei University. I have previously worked at Guohai Securities Co., Ltd., Wanjia Fund Management Co., Ltd., Wanjia Gongying Asset Management Co., Ltd., and Beijing Yuntong Law Firm. Since August 2023, I have served as Deputy General Manager and Director of the Investment Banking Department V at Pacific Securities Co., Ltd. Since June 2020, I have served as an independent director of the Company.
I do not hold any other positions in the Company besides that of an independent director. I have no direct or indirect interest relationship with the Company or its controlling shareholder and actual controller, nor any other relationship that may affect my independent and objective judgment. Therefore, I meet the qualification requirements for an independent director, have no circumstances that affect my independence, and comply with the relevant regulations on the independence of independent directors stipulated in the "Administrative Measures for Independent Directors of Listed Companies," the "Articles of Association," and the "Independent Director Work System of Beijing Remate Medical Technology Co., Ltd."
II. Overview of Performance in the Year
(I) Attendance at Board and Shareholder Meetings
In 2025, the Company held a total of 5 board meetings, 3 shareholder meetings, and 2 independent director special committee meetings. In accordance with relevant laws, regulations, and the "Articles of Association," I personally attended all 5 board meetings, 3 shareholder meetings, and 2 independent director special committee meetings. I did not have any absences or miss two consecutive board meetings without personal attendance. During the meetings, I conscientiously reviewed all proposals, actively participated in discussions, and gained a thorough understanding of the Company's relevant matters before offering constructive suggestions and expressing professional, independent opinions, thereby exercising my voting rights rigorously. I believe that the convening and holding procedures of the Company's board and shareholder meetings in 2025 complied with legal regulations, and major business decisions and other significant matters underwent relevant approval procedures, which were legal and effective. I voted in favor of all proposals at the board and its special committees, with no dissenting opinions, objections, or abstentions.
(II) Independent Director Special Committee Meetings
In 2025, I maintained sufficient communication with the Company's board of directors and management regarding matters reviewed by the board and attended independent director special committee meetings after thoroughly understanding the Company's operations. I expressed my consent on the following matters:
- On April 17, 2025, the third meeting of the third Board of Directors of the Company was held, and the "Proposal on the Estimated Daily Related Party Transactions for 2025" was deliberated and approved.
- On August 27, 2025, the fifth meeting of the third Board of Directors of the Company was held, and the "Proposal on the Addition of Estimated Daily Related Party Transactions for 2025" was deliberated and approved.